{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:47:05Z","timestamp":1772203625088,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"DOI":"10.7759\/cureus.45087","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T10:58:53Z","timestamp":1694516333000},"source":"Crossref","is-referenced-by-count":1,"title":["The Stiff Joint: Comparative Evaluation of Monotherapy and Combination Therapy With Urate Lowering Agents in Managing Acute Gout"],"prefix":"10.7759","author":[{"given":"Okelue E","family":"Okobi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Oletu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adaeze B","family":"Chukwuedozie-Echeazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine C","family":"Keke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyinyechukwu B","family":"Nwachukwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrietta  S","family":"Akunne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinwendum U","family":"Ekpemiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uchechukwu S","family":"Oranika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngozi T","family":"Akueme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oyewole E","family":"Akanle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buchi C","family":"Ogbuagu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda A","family":"Mbah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1221732","article-title":"Overview of serum uric acid treatment targets in gout: why less than 6 mg\/dL?.","volume":"128","author":"Ruoff G","year":"2016","unstructured":"Ruoff G, Edwards NL. Overview of serum uric acid treatment targets in gout: why less than 6 mg\/dL?.. Postgrad Med. 2016, 128:706-15. 10.1080\/00325481.2016.1221732","journal-title":"Postgrad Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna D","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al.. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012, 64:1431-46. 10.1002\/acr.21772","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub RA","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010, 62:1060-8. 10.1002\/art.27327","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.151.4.726","article-title":"Female gout: clinical spectrum and uric acid metabolism.","volume":"151(4)","author":"Puig JG","year":"1991","unstructured":"Puig JG, Mich\u00e1n AD, Jim\u00e9nez ML, et al.. Female gout: clinical spectrum and uric acid metabolism. . Archives of internal medicine. 1991,  151(4):726-732. 10.1001\/archinte.151.4.726","journal-title":"Archives of internal medicine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu Y","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011, 63:3136-41. 10.1002\/art.30520","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/ar3272","article-title":"Contemporary epidemiology of gout in the UK general population","volume":"13","author":"Cea Soriano L","year":"2011","unstructured":"Cea Soriano L, Rothenbacher D, Choi HK, Garc\u00eda Rodr\u00edguez LA. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011, 13:R39. 10.1186\/ar3272","journal-title":"Arthritis Res Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21837","article-title":"Gout-related health care utilization in US emergency departments, 2006 through 2008","volume":"65","author":"Garg R","year":"2013","unstructured":"Garg R, Sayles HR, Yu F, Michaud K, Singh J, Saag KG, Mikuls TR. Gout-related health care utilization in US emergency departments, 2006 through 2008. Arthritis Care Res (Hoboken). 2013, 65:571-7. 10.1002\/acr.21837","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty M","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, et al.. Gout: why is this curable disease so seldom cured?. Ann Rheum Dis. 2012, 71:1765-70. 10.1136\/annrheumdis-2012-201687","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study","volume":"71","author":"Spencer K","year":"2012","unstructured":"Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012, 71:1490-5. 10.1136\/annrheumdis-2011-200801","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi HK","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005, 143:499-516. 10.7326\/0003-4819-143-7-200510040-00009","journal-title":"Ann Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24612","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis","volume":"61","author":"Kim SY","year":"2009","unstructured":"Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009, 61:885-92. 10.1002\/art.24612","journal-title":"Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20344","article-title":"Hyperuricemia and incident hypertension: a systematic review and meta-analysis","volume":"63","author":"Grayson PC","year":"2011","unstructured":"Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011, 63:102-10. 10.1002\/acr.20344","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker MA","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al.. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005, 353:2450-61. 10.1056\/NEJMoa050373","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/2047487313514895","article-title":"Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis","volume":"22","author":"Clarson LE","year":"2015","unstructured":"Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015, 22:335-43. 10.1177\/2047487313514895","journal-title":"Eur J Prev Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette P","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al.. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017, 76:29-42. 10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.17.05188-6","article-title":"Change gout: the need for a new approach","volume":"108","author":"Punzi L","year":"2017","unstructured":"Punzi L. Change gout: the need for a new approach. Minerva Med. 2017, 108:341-9. 10.23736\/S0026-4806.17.05188-6","journal-title":"Minerva Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05272-4","article-title":"Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials","volume":"40","author":"Fan M","year":"2021","unstructured":"Fan M, Liu J, Zhao B, Wu X, Li X, Gu J, Schlesinger N. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clin Rheumatol. 2021, 40:683-92. 10.1007\/s10067-020-05272-4","journal-title":"Clin Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.39977","article-title":"2016 ACR\/ARHP annual meeting abstract supplement","volume":"68 Suppl 10","year":"2016","unstructured":"2016 ACR\/ARHP annual meeting abstract supplement. Arthritis Rheumatol. 2016, 68 Suppl 10.1-4550. 10.1002\/art.39977","journal-title":"Arthritis Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double\u2010blind, placebo\u2010controlled study in gout patients with an inadequate response to standard\u2010of\u2010care allopurinol (a US\u2010based study)","volume":"69","author":"Saag KG","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, et al.. Lesinurad combined with allopurinol: a randomized, double\u2010blind, placebo\u2010controlled study in gout patients with an inadequate response to standard\u2010of\u2010care allopurinol (a US\u2010based study). Arthritis Rheumatol. 2017, 69:203-12. 10.1002\/art.39840","journal-title":"Arthritis Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1788-4","article-title":"Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study","volume":"21","author":"Dalbeth N","year":"2019","unstructured":"Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Res Ther. 2019, 21:8. 10.1186\/s13075-018-1788-4","journal-title":"Arthritis Res Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche AK","year":"2017","unstructured":"Tausche AK, Alten R, Dalbeth N, et al.. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017, 56:2170-8. 10.1093\/rheumatology\/kex350","journal-title":"Rheumatology (Oxford)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker MA","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010, 12:R63. 10.1186\/ar2978","journal-title":"Arthritis Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1757456","article-title":"Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore","volume":"23","author":"Pruis SL","year":"2020","unstructured":"Pruis SL, Jeon YK, Pearce F, Thong BY, Aziz MI. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore. J Med Econ. 2020, 23:838-47. 10.1080\/13696998.2020.1757456","journal-title":"J Med Econ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.51847\/RkCPaycprc","article-title":"An overview on the role of xanthine oxidase inhibitors in gout management","volume":"12","author":"Alghamdi AA","year":"2021","unstructured":"Alghamdi AA, Althumali JS, Almalki MMM, et al..  An overview on the role of xanthine oxidase inhibitors in gout management . Arch Pharm Pract. 2021, 12:94-99. 10.51847\/RkCPaycprc","journal-title":"Arch Pharm Pract"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05079-3","article-title":"Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review","volume":"39","author":"Hu AM","year":"2020","unstructured":"Hu AM, Brown JN. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review. Clin Rheumatol. 2020, 39:3287-94. 10.1007\/s10067-020-05079-3","journal-title":"Clin Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.21608\/eajbsc.2023.308858","article-title":"Gout: A reviewing of the recent literature","volume":"15(2)","author":"Hassan HS","year":"2023","unstructured":"Hassan HS, Al-Osami MJ, Al-Hakeimand HK, et al.. Gout: A reviewing of the recent literature. C, Physiology and Molecular Biology. 2023,  15(2):51-58. 10.21608\/eajbsc.2023.308858","journal-title":"C, Physiology and Molecular Biology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261940","article-title":"Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients","volume":"17","author":"van de Laar CJ","year":"2022","unstructured":"van de Laar CJ, Janssen CA, Janssen M, Oude Voshaar MA, Al MJ, van de Laar MA. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients. PLoS One. 2022, 17:e0261940. 10.1371\/journal.pone.0261940","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04739-3","article-title":"Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients","volume":"38","author":"Presa M","year":"2019","unstructured":"Presa M, P\u00e9rez-Ruiz F, Oyag\u00fcez I. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. Clin Rheumatol. 2019, 38:3521-8. 10.1007\/s10067-019-04739-3","journal-title":"Clin Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/nu12123794","article-title":"A 12-week, multicenter, randomized, double-blind, placebo-controlled clinical trial for evaluation of the efficacy and safety of DKB114 on reduction of uric acid in serum","volume":"12","author":"Park YH","year":"2020","unstructured":"Park YH, Kim DH, Lee JS, Jeong HI, Lee KW, Kang TH. A 12-week, multicenter, randomized, double-blind, placebo-controlled clinical trial for evaluation of the efficacy and safety of DKB114 on reduction of uric acid in serum. Nutrients. 2020, 12:10.3390\/nu12123794","journal-title":"Nutrients"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O'Dell JR","year":"2022","unstructured":"O'Dell JR, Brophy MT, Pillinger MH, et al.. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. 2022, 1:10.1056\/evidoa2100028","journal-title":"NEJM Evid"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy JS","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, et al.. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011, 306:711-20. 10.1001\/jama.2011.1169","journal-title":"JAMA"},{"key":"ref32","article-title":"Pyrazinamide-induced hyperuricemia","volume":"39","author":"Pham AQ","year":"2014","unstructured":"Pham AQ, Doan A, Andersen M. Pyrazinamide-induced hyperuricemia. P T. 2014, 39:695-715.","journal-title":"P T"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S85193","article-title":"Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males","volume":"9","author":"Shen Z","year":"2015","unstructured":"Shen Z, Rowlings C, Kerr B, et al.. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des Devel Ther. 2015, 9:3423-34. 10.2147\/DDDT.S85193","journal-title":"Drug Des Devel Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz F","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016, 75:1074-80. 10.1136\/annrheumdis-2015-207919","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/0897190017734427","article-title":"Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout","author":"Huneycutt E","year":"2017","unstructured":"Huneycutt E, Board C, Clements JN. Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout. J Pharm Pract. 2017, 897190017734427. 10.1177\/0897190017734427","journal-title":"J Pharm Pract"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth N","year":"2017","unstructured":"Dalbeth N, Jones G, Terkeltaub R, et al.. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017, 69:1903-13. 10.1002\/art.40159","journal-title":"Arthritis Rheumatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0461-y","article-title":"Lesinurad: a review in hyperuricaemia of gout","volume":"34","author":"Deeks ED","year":"2017","unstructured":"Deeks ED.  Lesinurad: a review in hyperuricaemia of gout. Drugs Aging. 2017, 34:401-10. 10.1007\/s40266-017-0461-y","journal-title":"Drugs Aging"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S97959","article-title":"Guideline development for the management of gout: role of combination therapy with a focus on lesinurad","volume":"11","author":"Jones G","year":"2017","unstructured":"Jones G, Panova E, Day R. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des Devel Ther. 2017, 11:3077-81. 10.2147\/DDDT.S97959","journal-title":"Drug Des Devel Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39469","article-title":"Assessing the relationship between health information technology use and self-rated health among adults with chronic low back pain in the United States","volume":"15","author":"Okobi OE","year":"2023","unstructured":"Okobi OE, Odoma VA, Ogochukwu OA, et al.. Assessing the relationship between health information technology use and self-rated health among adults with chronic low back pain in the United States. Cureus. 2023, 15:e39469. 10.7759\/cureus.39469","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/183731-the-stiff-joint-comparative-evaluation-of-monotherapy-and-combination-therapy-with-urate-lowering-agents-in-managing-acute-gout","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:05Z","timestamp":1707508145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/183731-the-stiff-joint-comparative-evaluation-of-monotherapy-and-combination-therapy-with-urate-lowering-agents-in-managing-acute-gout"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.45087","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,12]]}}}